OGN Oct 2023 30.000 put
| Previous close | 6.89 |
| Open | 6.70 |
| Bid | 8.10 |
| Ask | 9.30 |
| Strike | 30.00 |
| Expiry date | 2023-10-20 |
| Day's range | 6.70 - 6.89 |
| Contract range | N/A |
| Volume | |
| Open interest | 97 |
CNW GroupORGANON CANADA TO SUPPORT LE CHAÎNON BY FUNDING THE INITIAL CONSTRUCTION PHASE OF ITS MEDICAL CLINIC
As part of Le Chaînon's 90th anniversary, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is announcing a contribution of $90,000 to help fund the mission of Le Chaînon and the creation of an in-house medical clinic.
Business WireOrganon Reports Results for the First Quarter Ended March 31, 2023
JERSEY CITY, N.J., May 04, 2023--Organon Reports Results for the First Quarter Ended March 31, 2023
ZacksAnalysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireOrganon To Report First Quarter and Host Conference Call on May 4, 2023
JERSEY CITY, N.J., April 20, 2023--Organon To Report First Quarter and Host Conference Call on May 4, 2023
Business WireOrganon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
JERSEY CITY, N.J., March 07, 2023--Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
CNW GroupOrganon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace
Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is excited to share that in line with National Employee Appreciation Day on March 3, it has received the Women in Governance Parity Certification SME 1. The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace. Through integrating numerous programs and policies across the organization, Organon Canada ha
CNW GroupAhead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health
For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers and others – to consider the consequences of the growing health disparities that women are currently facing. In Canada, for the second consecutive year, the company
Business WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
JERSEY CITY, N.J., February 16, 2023--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022.
Business WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
JERSEY CITY, N.J., February 06, 2023--Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
ZacksWill Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Business WireOrganon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
JERSEY CITY, N.J., January 05, 2023--Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
Business WireOrganon To Present at the 41st Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., December 15, 2022--Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
Business WireOrganon Appoints Kirke Weaver as General Counsel and Corporate Secretary
JERSEY CITY, N.J., December 12, 2022--Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
Business WireOrganon To Present at the Piper Sandler 34th Annual Healthcare Conference
JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.
ACCESSWIREOrganon Announces Formal Commitment to FP2030 To Help Prevent 120 Million Unintended Pregnancies in Low- and Middle-Income Countries Around the World
Organon (NYSE:OGN), a global women's healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement.
CNW GroupOrganon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost
Organon (NYSE: OGN), a global women's health company, today announced the availability and distribution of Ontruzant®, a biosimilar of Herceptin®, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).1
CNW GroupOrganon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer
Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur
Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2022
JERSEY CITY, N.J., November 03, 2022--Organon reports results for the third quarter ended September 30, 2022
Business WireOrganon To Report Third Quarter Results and Host Conference Call on November 3, 2022
JERSEY CITY, N.J., October 20, 2022--Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
CNW GroupOrganon Canada reinforces the need to raise awareness and access for contraception methods with nearly half of pregnancies unplanned
On World Contraception Day (September 26), Organon (NYSE: OGN), a global women's health company, is launching Act with Her, a multi-faceted approach to help tackle the global health issue of unintended pregnancies (UIPs) and to improve access to contraception. Organon is proud to support the Society of Obstetricians and Gynaecologists of Canada (SOGC) to reinforce the importance of education and awareness in reducing unplanned pregnancies in Canada through roundtable discussions. In addition, Or
Business WireSamsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
INCHEON, Korea & JERSEY CITY, N.J., August 17, 2022--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
Business WireOrganon Reports Results for the Second Quarter Ended June 30, 2022
JERSEY CITY, N.J., August 04, 2022--Organon reports results for the second quarter ended June 30, 2022
Business WireOrganon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
JERSEY CITY, N.J., July 28, 2022--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
Business WireOrganon To Report Second Quarter Results and Host Conference Call on August 4, 2022
JERSEY CITY, N.J., July 21, 2022--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company’s webcast and call scheduled for 8:30 a.m. EDT.
Business WireOrganon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
JERSEY CITY, N.J., June 13, 2022--Organon announces first biosimilars business deal with a global license agreement with Henlius.